JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Trial Details

NCT ID
NCT05490472
Phase
PHASE1 / PHASE2
Sponsor
Jacobio Pharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • JAB-2485 (Aurora A inhibitor)
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Dallas, Texas, United States|32.78306,-96.80667
  • Salt Lake City, Utah, United States|40.76078,-111.89105
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Must be able to provide an archived tumor sample
  • Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor
  • Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →